Introduction
Cytomegalovirus (CMV) infection is ubiquitous in the general population and rarely produces symptoms in the immunocompetent infant, child, or adult. CMV-induced illness may be serious in individuals with impaired immune systems, however, including those who are HIV-infected, patients who have received solid-organ or hematopoietic transplants, and infants infected in utero. In the developed world, congenital CMV infection is the most common congenital viral infection, present in about 1% (0.5%-2%) of all live births [1] . This corresponds to approximately 40,000 infants born with CMV infection every year in the United States, making this infection a more common cause of birth defects in newborns than other, better-known childhood conditions such as Down syndrome, fetal alcohol syndrome, or spina bifida [2••] . Rates of congenital CMV infection tend to parallel those of maternal seropositivity. It is estimated that in the United States every year, about 27,000 women acquire primary CMV infection during pregnancy [3••] . Young maternal age, single marital status, and nonwhite race are associated with higher rates of congenital CMV infection. Women with occupations associated with increased exposure to young children, such as teachers and day-care providers, may be at increased risk of acquiring primary CMV infections [4] .
Transmission of CMV appears to be more common in the setting of a primary maternal infection. Primary maternal infection during pregnancy results in intrauterine infection of the fetus in 30% to 40% of cases, compared with a risk of about 1% in women with preconception immunity who are reinfected during pregnancy (nonprimary infection) [5, 6] . Although preexisting maternal immunity reduces the incidence of maternal-fetal transmission, recent evidence seems to suggest that the severity of congenital CMV disease in the infected newborn is similar following primary or nonprimary maternal infections [7] [8] [9] [10] . Thus, intervention programs could be targeted both to the woman with a primary CMV infection identified during pregnancy and to the newborn infant identified with congenital CMV infection during newborn screening. Caution must be exercised in interpreting the results of virologic tests obtained beyond 14 to 21 days of age, because the identification of CMV in such infants may represent postnatal acquisition of infection, typically through breast-feeding [11] .
Early signs and symptoms are apparent at birth in 10% to 15% of all children with congenital CMV infection. Thus, 4000 to 6000 infants are born with symptomatic congenital CMV disease each year in the United States. Infection in the symptomatic infant may involve any organ and ranges from mild, isolated, transient illness to severe, fulminant dissemination resulting in up to 20% perinatal mortality [12] . Fulminant illness is characterized by jaundice, hepatosplenomegaly, lethargy, respiratory distress, seizures, and petechial rash. Infants may exhibit a wide spectrum of disease, including hemolysis, bone marrow suppression, hepatitis, pneumonitis, enteritis, and nephritis [13] [14] [15] . Antiviral therapy may be lifesaving for infants with overwhelming infection and severe organ disease.
Of major importance is the issue of central nervous system (CNS) involvement in congenital CMV infection. Infants who are symptomatic in the newborn period commonly present with cerebral lesions, including meningoencephalitis, calcifications, microcephaly, disturbances in neuronal migration, germinal matrix cysts, ventriculomegaly, and cerebellar hypoplasia [16] . CNS disease usually results in at least one of the following signs and symptoms: lethargy, hypotonia, seizures, hearing deficit, or abnormal eye examination. CNS involvement may be corroborated by abnormal imaging studies (cranial CT, brain MRI, or head ultrasound) [17, 18] . Figure 1 shows an example of an abnormal MRI scan of a symptomatic, congenitally infected infant. The risk of long-term neurodevelopmental disabilities is high in this setting; they are observed in 50% to 90% of children who are symptomatic at birth. Possible longterm sequelae include microcephaly, hearing loss, motor deficits (paresis/paralysis), cerebral palsy, mental retardation, seizures, ocular abnormalities (chorioretinitis, optic atrophy), and learning disabilities (Table 1) .
In contrast, long-term neurodevelopmental injury is less likely in congenitally infected infants who are asymptomatic at birth. Such injury is typically limited to hearing deficits [19] [20] [21] [22] . Sensorineural hearing loss (SNHL), the most frequent sequela of congenital CMV infection, may occur in both symptomatic and asymptomatic infected infants. The bulk of the evidence regarding the potential benefits of antiviral therapies for congenital CMV infection relates to the issue of SNHL; thus, this is an area of unique importance in the assessment of the role of treatment of congenital CMV infection. The incidence of hearing loss among children with congenital CMV infection ranges from 10% to 15% among infants who are asymptomatic at birth to as many as 60% of infants with symptomatic congenital infection [23, 24] . SNHL can be progressive and fluctuating and can range in severity from a unilateral, mild hearing deficit to severe, bilateral, profound deafness [25] [26] [27] . Patients with symptomatic congenital CMV disease with clinical and laboratory findings suggesting disseminated infection at birth (eg, petechiae, hepatosplenomegaly, CNS abnormalities) 
